Reiser et al. developed the iPSC-derived FT555 CAR-NK cell product targeting GPRC5D and CD38, used alongside daratumumab, providing a scalable, off-the-shelf therapeutic option for broad MM patient access [245]. Here, GPRC5D is linked to Miyoshi myopathy.